AQT70Agilent Technologies, Inc.·NYSE
173.07-0.47%
TA
Loading chart...
Screen all →
Snapshot
IndexS&P 500P/E34.07EPS (ttm)5.08Insider Own0.57%Shs Outstand281.97MPerf Week0.06%
Market Cap48.80BForward P/E25.73EPS next Y6.73Insider Trans-0.14%Shs Float280.96MPerf Month0.13%
Enterprise Value50.99BPEG3.49EPS next Q1.72Inst Own61.67%Short Float1.87%Perf Quarter25.51%
Income1.44BP/S6.62EPS this Y11.29%Inst Trans0.00%Short Ratio2.32Perf Half Y49.78%
Sales7.37BP/B6.63EPS next Y8.43%ROA10.31%Short Interest5.24MPerf YTD27.19%
Book/sh26.11P/C27.76EPS next 5Y9.75%ROE20.47%52W High179.11 -3.37%Perf Year18.65%
Cash/sh6.23P/FCF33.98EPS past 3/5Y3.02% 14.72%ROIC11.88%52W Low108.35 59.73%Perf 3Y59.35%
Dividend Est.1.02 (0.59%)EV/EBITDA25.06Sales past 3/5Y0.48% 5.41%Gross Margin53.73%Volatility3.32% 2.80%Perf 5Y12.92%
Dividend TTM1.02 (0.59%)EV/Sales6.92EPS Y/Y TTM14.67%Oper. Margin22.23%ATR (14)5.02Perf 10Y283.24%
Dividend Ex-DateOct 06, 2026Quick Ratio1.56Sales Y/Y TTM13.24%Profit Margin19.53%RSI (14)57.25Recom2.20
Dividend Gr. 3/5Y-11.27% 6.62%Current Ratio2.05EPS Q/Q18.25%SMA200.67%Beta1.23Target Price173.08
Payout19.86%Debt/Eq0.50Sales Q/Q8.06%SMA507.22%Rel Volume0.79Prev Close173.89
Employees18,200LT Debt/Eq0.45EarningsNov 23SMA20027.94%Avg Volume2.23MPrice173.07
IPO DateNov 18, 1999Option/ShortYes / YesEPS/Sales Surpr.8.85% 1.98%Net Debt/EBITDA1.08Volume1,760,200Change-0.47%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-07-26ReiteratedBarclaysOverweight$175 → $195
Sep-09-26ReiteratedUBSBuy$180 → $165
Sep-02-26ReiteratedJefferiesHold$130 → $155
Aug-27-26ReiteratedRBC CapitalOutperform$155 → $180
Aug-27-26ReiteratedStifel NicolausHold$170 → $180
Aug-27-26ReiteratedGoldman SachsBuy$170 → $175
Aug-27-26ReiteratedBarclaysOverweight$140 → $175
Aug-27-26ReiteratedEvercore ISI GroupOutperform$148 → $172
Aug-27-26ReiteratedBernsteinOutperform$180
Jul-06-26ReiteratedEvercore ISI GroupOutperform$160 → $148
Latest News· Times ET
Oct-23-26
Oct-21-26
Oct-14-26
Oct-13-26
Oct-12-26
Oct-05-26
Oct-02-26
Oct-01-26
Sep-30-26
Sep-29-26
Sep-26-26
Sep-25-26
Sep-23-26
Company

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

Ownership
Total institutional ownership61.67%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
10/31/2025
FY 2024
10/31/2024
FY 2023
10/31/2023
FY 2022
10/31/2022
FY 2021
10/31/2021
FY 2020
10/31/2020
FY 2019
10/31/2019
FY 2018
10/31/2018
Total Revenue7,3726,9486,510——————
Cost of Goods Sold Incl. D&A3,4113,3052,975——————
Gross Profit3,9613,6433,535——————
Selling, General and Administrative Excl. Other1,8441,7091,518——————
Research and Development485455479——————
Other Operating Expense-7050——————
Operating Income1,6391,4791,488——————
Interest Expense10611296——————
Unusual Expense
—————————
Non-Operating Income (Expense)12568129——————
Net Income Before Taxes1,6581,4351,521——————
Income Taxes218132232——————
Consolidated Net Income1,4401,3031,289——————
Net Income From Continuing Operations1,4401,3031,289——————
Net Income1,4401,3031,289——————
EPS (Recurring)5.094.594.44——————
EPS (Basic, Before Extraordinaries)5.094.594.44——————
EPS (Diluted)5.084.574.43——————
EBITDA2,0351,8351,874——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio34.0732.0329.42——————
Price To Sales Ratio6.625.965.80——————
Gross Margin53.7352.4354.30——————
Operating Margin22.2321.2922.86——————
Net Margin19.5318.7519.80——————
Shares Outstanding282283290——————
Market Capitalization48,80641,42037,790——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$187.88$165.94$144.00$122.05$100.11● Close Price0.00M0.62M1.23M1.85M2.47MUSD Trades VolumeOctNovDec2026FebMarAprMayJunJulAugSepOct
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Dolsten MikaelDirectorSep 04 '26Sale151.3863495,9724,924Sep 09
Dolsten MikaelDirectorMay 29 '26Sale135.421,600216,6725,548Jun 02
Dolsten MikaelDirectorDec 01 '25Sale149.812,600389,5114,973Dec 03
Gonsalves RodneyV.P., Corporate ControllerNov 26 '25Sale154.993,000464,95631,846Dec 01
MCDONNELL PADRAIGPresident and CEONov 18 '25Sale143.24911130,49232,058Nov 20
MCDONNELL PADRAIGPresident and CEONov 12 '25Option Exercise109.8612,4901,372,15145,938Nov 14
MCDONNELL PADRAIGPresident and CEONov 12 '25Sale150.0012,4901,873,50033,448Nov 14
MCDONNELL PADRAIGPresident and CEOSep 02 '25Sale124.882,000249,76033,448Sep 04
MCDONNELL PADRAIGPresident and CEOAug 01 '25Sale113.452,000226,90035,448Aug 04
MCDONNELL PADRAIGPresident and CEOJul 01 '25Sale117.441,508177,10037,448Jul 03
Brown Judy LDirectorJun 18 '25Sale116.5389041,677Jun 23
Podolsky Daniel KDirectorMar 31 '25Sale116.461,819211,84435,737Apr 02
Gonsalves RodneyV.P., Corporate ControllerMar 17 '25Sale121.981,908232,69121,786Mar 18
Rataj Sue H.DirectorMar 06 '25Sale126.386,971881,00919,640Mar 07
MCDONNELL PADRAIGPresident and CEOJan 21 '25Sale150.001,911286,65039,652Jan 23
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.